CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 106 enrolled
Drug / intervention
Insulin Glargine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00360698
NCT00360698Phase 4Completed

Comparison of Two Therapeutic Strategies for Treating Type 2 Diabetic Patients Poorly Controlled With Basal Insulin Associated With Oral Antidiabetic Drugs : 6-month Proof of Concept Study.

Sanofi·interventional·Posted Aug 7, 2006·Updated Aug 8, 2011

In Brief

A Phase 4 clinical trial evaluating Insulin Glargine, Glimepiride, and 2 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 106 participants across 3 sites in 3 countries.

Detailed Summary

To evaluate the efficacy of a single injection of glulisine before the main meal added to insulin glargine plus oral antidiabetic drugs (OADs) compared to insulin glargine plus OADs in Type 2 diabetic patients poorly controlled with basal insulin plus OADs.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesRussia, United Kingdom, United States
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 7, 2006
Enrollment StartJul 1, 2006
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 19.9 years ago

Interventions

Insulin Glarginedrug

One daily injection at bedtime

Glimepiridedrug

At same dosage as during the run-in period

Insulin Glulisinedrug

One bolus given before the main meal

Metformindrug

At same dosage as during the run-in period